Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Stenoparib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Allarity Adds Leaders To Advance Stenoparib PARP Program
    Allarity Adds Leaders To Advance Stenoparib PARP Program

    03 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/03/2957638/0/en/Allarity-Therapeutics-Strengthens-Leadership-with-Key-Appointments-to-Accelerate-Stenoparib-PARP-Inhibitor-Program.html

    GLOBENEWSWIRE
    03 Oct 2024
    Share Share
    Allarity Stenoparib Shows Extended Benefit in Advanced Ovarian Cancer
    Allarity Stenoparib Shows Extended Benefit in Advanced Ovarian Cancer

    25 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/25/2903722/0/en/Allarity-Therapeutics-Dual-PARP-Tankyrase-Inhibitor-Stenoparib-Continues-to-Show-Extended-Clinical-Benefit-in-Advanced-Ovarian-Cancer.html

    GLOBENEWSWIRE
    25 Jun 2024
    Share Share
    Allarity Reports Q1 Results, Clinical Benefits, NASDAQ Compliance
    Allarity Reports Q1 Results, Clinical Benefits, NASDAQ Compliance

    14 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/14/2881841/0/en/Allarity-Therapeutics-Reports-First-Quarter-Financial-Results-and-Highlights-including-Clear-Clinical-Benefits-from-Phase-2-Trial-NASDAQ-Compliance-and-Significant-Improvement-in-C.html

    GLOBENEWSWIRE
    14 May 2024
    Share Share
    Allarity Stenoparib Shows Clear Clinical Benefit and Achieves Milestone
    Allarity Stenoparib Shows Clear Clinical Benefit and Achieves Milestone

    02 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/02/2874113/0/en/Allarity-Therapeutics-Stenoparib-Shows-Clear-Clinical-Benefit-and-Achieves-Significant-Milestone-with-Early-Conclusion-of-Phase-2-Trial-in-Advanced-Ovarian-Cancer.html

    GLOBENEWSWIRE
    02 May 2024
    Share Share
    Allarity Strategic Focus on Accelerating Stenoparib Toward Regulatory Approval
    Allarity Strategic Focus on Accelerating Stenoparib Toward Regulatory Approval

    27 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/03/27/2853146/0/en/Allarity-Therapeutics-Makes-Strategic-Pivot-to-Focus-Solely-on-Accelerating-Stenoparib-Toward-Regulatory-Approval-in-Advanced-Recurrent-Ovarian-Cancer.html

    GLOBENEWSWIRE
    27 Mar 2024
    Share Share
    Allarity's Phase 2 Stenoparib Data Indicates Clinical Benefit in Ovarian Cancer
    Allarity's Phase 2 Stenoparib Data Indicates Clinical Benefit in Ovarian Cancer

    05 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/12/05/2790791/0/en/Allarity-s-Early-Phase-2-Stenoparib-Data-Indicates-Clinical-Benefit-in-Women-with-Advanced-Ovarian-Cancer-Selected-with-DRP-Companion-Diagnostic.html

    GLOBENEWSWIRE
    05 Dec 2023
    Share Share